JPM Day 1: Highlights

Follow updates from the JPM Annual Healthcare Conference - BioSpace will be tracking key updates here all day. All times are Eastern Standard.

1:30 p.m.: In November, the FDA accepted Sarepta Therapeutics’ Biologics License Application for the accelerated approval of SRP-9001 for Duchenne muscular dystrophy.